Skip to content

Study in Retinal Cells Transplantation for Retinitis pigmentosa

Safety and Efficacy Study in Fetal Photoreceptor Progenitor Cells Transplantation for Retinitis Pigmentosa

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TNRC-08000193
Enrollment
Unknown
Registered
2008-12-05
Start date
2008-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced retinitis pigmentosa

Interventions

Group 2:fetal photoreceptor progenitor cells transplantation
Group1:fetal neuroretinal cells transplantation

Sponsors

Southwest Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Clinical condition, bilateral expression of advanced retinitis pigmentosa; 2. Age range 18 to 50 years; 3. Visual acuity is worse than 10/200 by ETDRS vision testing in the operated eye, or the radius of view is less than 100 by visual field testing. Vision in the non-operated eye must be better than the operated eye; 4. Patient has signed informed consent for retinal transplantation and is willing to return for follow-up visits; 5. Macular has no detectable gross changes either clinically or on fluorescein angiography.

Exclusion criteria

Exclusion criteria: 1. Patient has medical problems that have a high risk of general anesthesia, such as metabolic, cadiovascular, hematopoietic or psychological system disorders; 2. Women in menstruation, pregnancy, perinatal prtiod and baby nursing periods; 3. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome; 4. Patient who has a history of corneal leukoma, cataract, uveitis, Coat's disease, diabetic retinopathy, glaucoma, or vitreous opacities that prevents visualization of the posterior pole; 5. Participating in another ophthalmic clinical trial or use of any other investigational new drugs within 3 months before the start of study treatment; 6. Intraocular surgery within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Static perimetry;Flash electroretinography;Multifocal electroretinography;Snellen Visual acuity;Optical coherent tomography;Fluorescein angiography;Pupillary light reflex;

Secondary

MeasureTime frame
Transplantation rejection;

Countries

China

Contacts

Public ContactYin Zhengqin
qinzyin@yahoo.com.cn+86 023 68754401

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026